NAD+ injections and IV drips: benefits, side effects and FDA status

NAD+ drips and shots have not been shown to give people more energy, sharper thinking or slower aging, which is what most clinics sell them for. NAD+ is not even a peptide. It is a coenzyme, a helper molecule every cell uses to turn food into energy, and it sits in our peptide index only because the same clinics offer it. No NAD+ drug is FDA-approved. What it does have, unlike most peptides here, is a compounding route: FDA lists it in 503A category 1 while it evaluates it.

What NAD+ is, and why it is not a peptide

NAD+ stands for nicotinamide adenine dinucleotide. It is two nucleotides joined through their phosphate groups: one carries nicotinamide, a form of vitamin B3, and the other carries adenine. A peptide, by contrast, is a short chain of amino acids. In cells, NAD+ shuttles electrons in the reactions that make energy, flipping between NAD+ and its reduced form, NADH. It is also used up by enzymes involved in DNA repair and cell signaling, which is the basis of the anti-aging interest.

The body makes NAD+ from dietary niacin, nicotinamide and tryptophan. Oral “precursors” such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are sold as supplements on the idea that they raise NAD+ levels. A 2026 narrative review of IV NAD+ noted that recent large human data indicate “whole-blood NAD+ concentrations do not decline with healthy aging,” which undercuts the simplest version of the marketing: that everyone’s NAD+ runs low with age and needs topping up.

NAD+ benefits: what the evidence shows

The real benefit of NAD+ is that you cannot live without it, and your cells make their own. The open question is whether adding more from outside helps a healthy person, and for drips and shots no trial has shown that it does.

Two things make the drip claims especially hard to support. First, NAD+ in the blood does not stay NAD+ for long. Enzymes on cell surfaces, most notably CD38, cut it into nicotinamide and ADP-ribose, and the 2026 narrative review says “it remains uncertain how much intact NAD+ enters cells.” A rise in blood levels does not show that muscle or brain got more. Second, the oral precursors have more human data than the drips do. They raise NAD+ markers and are generally well tolerated, yet the 2026 systematic review found their functional results mixed or null.

NAD+ IV drip vs injection

The two routes deliver very different amounts in very different ways, and neither has outcome data for wellness.

What the injection data show

The only controlled human data on NAD+ shots come from a 2026 preprint, which has not yet been peer reviewed. In one trial, 45 adults received placebo, NR or NAD+, each by vein, under the skin or into muscle, 100 mg a day for 3 days. Only 4 to 6 people were in each NAD+ group. Under the skin, NR and NAD+ “performed comparably,” and the authors reported no severe or unexpected adverse events attributable to either. The trials were funded by ChromaDex, which makes NR and holds patents on its use, and the authors describe their findings as a preliminary safety signal. That is a tolerability check in a few dozen people over days. It says nothing about benefit, and nothing about the weekly injections some clinics sell for months.

NAD+ infusion reactions

Drips are where most of the reported side effects happen, and the speed of the drip matters. The 2026 narrative review lists nausea, cramping, flushing and chest discomfort, “particularly at faster infusion rates.”

The clearest real-world picture comes from a 2026 review of records at a wellness clinic. Six clients had 500 mg of NAD+ in 500 mL of saline on four consecutive days, controlling their own drip rate. All six reported moderate to severe abdominal cramping, diarrhea, nausea, vomiting, faster heart rate, throat pain, congestion and chest pressure, and they slowed their drips because of it. The symptoms ended when each infusion finished, and no adverse events were documented. Eight clients given NR instead finished in about 37 minutes, with milder effects. All the authors worked for the clinic, and six people is a very small group. The 2019 pilot, which ran 750 mg over 6 hours, roughly 2 mg a minute, reported no adverse events at that slow rate.

Some reactions have nothing to do with NAD+ itself:

• Contamination. In January 2026 FDA warned a 503B outsourcing facility after three patients went to the emergency room with low blood pressure, uncontrollable shaking, shivering and body aches after NAD+ from the same vial. An unopened vial from that lot held 3,360 EU/mL of bacterial endotoxin, a toxin that causes fever and shock. The firm had recalled its sterile products in July 2025.
• The line itself. Any drip can cause bruising, vein irritation or infection at the needle site.
• Long term. Unknown. Reviews note that long-term safety data are lacking.

Low blood pressure, shaking and chills after a drip, as in FDA’s contamination case, are not the usual NAD+ discomfort and need urgent medical care.

FDA status in detail

FDA’s January 2025 interim policy sets four conditions for compounding with a category 1 substance: the substance must appear in category 1; every manufacturer of the bulk ingredient must be registered with FDA; the ingredient must come with a valid certificate of analysis; and the compounded drug must meet every other condition of section 503A, which includes a prescription for an individual patient. FDA can move a substance out of category 1 if it identifies safety risks. The exact salt form matters: a pharmacy using the category 3 form is outside the policy.

The HHS enforcement policy announced on October 28, 2026 is a separate thing. As of November 2, 2026, it covers six peptides (BPC-157, TB-500, MOTS-c, KPV, epitalon and semax) under ten conditions, approves none of them, and does not include NAD+. Nothing about NAD+’s route changed that week.

None of this makes compounded NAD+ an approved drug. FDA says it “does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.” In August 2026 FDA reported at least 30 patients with sepsis-like reactions after IV glutathione compounded from a supplement-grade ingredient, a reminder that ingredient grade matters for anything infused.

What the human studies show

The doses differ enormously: the heart failure trial used 10 mg a day, while drips in the other studies used 500 to 1,000 mg, so the trial says nothing about drip-clinic protocols. A 2026 dermatology review of IV “longevity therapy,” including NAD+, concluded it “should be regarded as an experimental intervention.” For nasal sprays, we found no human studies at all.

WADA status

NAD+ is not a named substance on the 2026 WADA Prohibited List. The way it is often given can be a problem: prohibited method M2.2 bans “intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period” except those received legitimately in hospital treatment, surgery or clinical investigations. A 500 mL wellness drip breaches that limit whatever is in the bag.

Research-labeled NAD+ powder

NAD+ is also sold online as powder marked “for research use only.” That label, under 21 CFR 312.160, covers shipment for laboratory animal or test-tube work, and these products are not legal to use on people. They are not the compounded product described above: there is no prescription, no pharmacy, no verified sterility and no registered-manufacturer requirement. The guide to reading a COA explains why a seller’s certificate does not fill that gap.

NAD+ has no approved column, so only the last two kinds exist for it.

Questions to ask before an NAD+ drip or shot

• Who made it? A state-licensed 503A pharmacy compounding for you, on a prescription with your name, is the route FDA’s category 1 policy describes.
• Which form? NAD or NADH is in category 1; the disodium salt trihydrate is in category 3 and outside the policy.
• What grade was the ingredient? FDA’s glutathione and NAD+ actions both involved sterile injectables gone wrong. Ask whether the bulk ingredient came with a certificate of analysis from an FDA-registered maker.
• How much, and how fast? Ask the dose in milligrams, the bag volume and the planned infusion time, since faster drips bring more symptoms.
• What happens if I feel unwell? Someone should be able to slow or stop the drip and recognize a reaction that needs emergency care.
• What result should I expect? Since no trial shows a wellness benefit, a clinic promising one is promising more than the evidence holds.

The peptide therapy guide covers checking a clinic and pharmacy more broadly.

Who should be cautious, and what to watch for

• Anyone expecting proven benefit. No published trial supports the wellness claims for injected or infused NAD+.
• People with heart or kidney disease, or who are pregnant. These groups have not been studied in wellness use.
• Symptoms during a drip. Chest discomfort, severe cramping or shortness of breath are reasons to stop and get medical attention.
• Product and pharmacy. A legitimate compounded product has a prescription, a licensed pharmacy’s label, the patient’s name and a beyond-use date. The guide to peptide safety covers compounding risks, and the FDA status tracker carries NAD+ in its own row.